Lack of clarity on tapentadol SR
It is not yet possible to suggest which patients may gain the most benefit from tapentadol SR, according to an NPS MedicineWise review
This is because the clinical trials produced mixed results and were limited by a high study drop-out rate, according to the review published in the latest issue of NPS RADAR.
Tapentadol is PBS listed as an alternative to other opioids such as oxycodone for chronic, severe disabling pain that doesn’t respond to non-opioid analgesics.
It acts primarily by